GSK Navigates COVID-19 Opportunities And Obstacles In Q1
Executive Summary
While some parts of the world stocked up on OTC drugs, others went into total lock down, resulting in a mixed picture for GSK's Consumer Healthcare performance in Q1.
You may also be interested in...
GSK Sees Other Side Of Consumer Health Stockpiling Coin, Looks Ahead To Business Split
GSK reports pandemic-related stockpiling in 2020 combined with a weak cold and flu season in Q1 drove its consumer health sales down 9%, with the sharpest downturn in respiratory products sales. The firm expects in the second half of the year to see “more normal consumer trends.”
Q1 Consumer Health Earnings Preview: GSK, Sanofi And Bayer
Likely talking points when three of the biggest global consumer health players report Q1 results include: GSK's separation plan and the influence of a new major investor; Sanofi's program to divest over half of its OTC brands; and Bayer's ability to sustain higher sales of dietary supplements post-COVD-19.
GSK Promises 'Greater Transparency' From Consumer Brand Reshuffle
In the wake of its joint venture with Pfizer, GSK Consumer Healthcare has shaken up how it reports its sales by category to highlight the "main drivers" of performance.